Guggenheim made no change to the firm’s Buy rating on Agilon Health. The firm says the 2024 revenue guidance of $5.5B+ was the "floor" for the target and likely didn’t really represent the company’s expectations for revenue coming in below the Street, and the news of the higher MA pay raise makes the $5.5B+ target look even more conservative, the analyst tells investors in a research note.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AGL:
- Final Medicare Advantage rates positive for managed care, says JPMorgan
- TD Cowen healthcare analyst to hold analyst/industry conference call
- Agilon Health to host investor day
- Holland PHO and Agilon Health form West Michigan partnership, no terms
- Premier Health forms long-term partnership with Agilon Health, no terms
